Endoscopic Vessel Harvesting Global Market to 2027 Insight: Featuring Cardio Medical, Karl Storz and Terumo Among Others

Endoscopic Vessel Harvesting Global Market Trajectory & Analytics report has been added to ResearchAndMarkets.com’s offering.

Amid the COVID-19 crisis, the global market for Endoscopic Vessel Harvesting estimated at US$456.3 Million in the year 2020, is projected to reach a revised size of US$580.9 Million by 2027, growing at a CAGR of 3.5% over the analysis period 2020-2027.

EVH Systems, one of the segments analyzed in the report, is projected to record a 3.8% CAGR and reach US$293.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Endoscopes segment is readjusted to a revised 3.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $134.2 Million, While China is Forecast to Grow at 3.3% CAGR

The Endoscopic Vessel Harvesting market in the U.S. is estimated at US$134.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$103.4 Million by the year 2027 trailing a CAGR of 3.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.2% and 2.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Accessories Segment to Record 2.9% CAGR

In the global Accessories segment, USA, Canada, Japan, China and Europe will drive the 3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$62.5 Million in the year 2020 will reach a projected size of US$77 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$64.7 Million by the year 2027.

Select Competitors (Total 40 Featured):

  • Cardio Medical
  • Getinge
  • Karl Storz
  • Livanova
  • MAQUET Holding B.V. & Co. KG
  • Med Europe S.r.l. (Elite Life Care)
  • Medical Instruments Spa
  • Saphena Medical
  • Terumo

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

  • UNITED STATES
  • CANADA
  • JAPAN
  • CHINA
  • EUROPE
  • FRANCE
  • GERMANY
  • ITALY
  • UNITED KINGDOM
  • REST OF EUROPE
  • ASIA-PACIFIC
  • REST OF WORLD

IV. COMPETITION

  • Total Companies Profiled: 40

For more information about this report visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”